Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-07-21
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech that uses its proprietary data, automated labs, and Recursion OS to discover drug candidates and earn collaboration revenue with biopharma partners.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof, Not Hype, Drives the Upside
A large cash balance limits near-term existential risk, but the real prize is whether 2026-2028 turns an AI-heavy discovery platform into repeatable human clinical wins. If that happens, the stock can rerate materially without needing a mega-blockbuster franchise by 2031.

Analysis

Thesis
Recursion is a cash-backed option on proving that a proprietary data-model-lab loop can create medicines repeatedly, not just once; if REC-4881 gets a credible regulatory path and at least one more owned program validates in humans, the stock can rerate from discovery contractor optionality toward repeatable drug-creation value.
Last Economy Alignment
Cheaper cognition helps Recursion because its edge sits in proprietary data, automated experimentation, and owned assets rather than a thin software wrapper. The score stops short of elite because biology, FDA design, and partner proof still bottleneck value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
This is mainly a rerating case. If one lead asset gets a credible approval path, a second owned program adds human proof, and new deals shift toward richer downstream economics, investors can value the company less like a cash-burning discovery vendor and more like a repeatable medicine-creation engine. The upside is meaningful, but still bounded by clinical and financing reality.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Recursion can run AI-driven discovery workflows; it is whether those workflows convert into regulator-usable human evidence fast enough to outrun cash burn and partner bargaining pressure. REC-4881 path clarity is the dominant gate, a second owned-program proof point matters almost as much, and any stumble there can push the company back toward lumpy collaboration value and future dilution.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.54
They own a data-and-lab loop that gets smarter with every experiment, so cheaper AI helps them more than it hurts them. The catch is that biology and the FDA still decide whether that loop turns into valuable drugs and durable partner economics.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.25
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case